The lawsuit, filed on Oct. 7, claimed that the FDA’s decision to remove Lilly’s tirzepatide from its shortage list was ‘reckless and arbitrary’ and that the drugs were still in short supply.

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the drugs, was ...

In December, the FDA declared that Eli Lilly's weight loss and diabetes medication tirzepatide, sold under the brand names Mounjaro and Zepbound, was no longer in short supply. That meant pharmacies ...

The US Food and Drug Administration (FDA) has added haemodialysis bloodlines to its medical device shortages list amid supply disruptions. The agency expects the shortage to continue into late ...

The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in December after the FDA found them to no longer be in short supply. The FDA ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

In its lawsuit, filed in February 2025, the association alleged that the FDA had acted recklessly in removing semaglutide from the shortage list while there was evidence that the drugs were still ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. GROUP SAID FDA ACTED RECKLESSLY 3rd party Ad.

US Judge Upholds FDA's Removal of Ozempic, Wegovy From Drug Shortage List (Corrects paragraph 10 and third bullet to remove reference to Novo Nordisk's CEO leaving the company. He has announced ...